Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 15 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Alopecia areata
  • Focus Registrational; Therapeutic Use
  • Acronyms BRAVE-AA1
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 01 Mar 2024 Results (from studies BRAVE-AA1 and BRAVE-AA2) assessing efficacy and safety of baricitinib for severe AA through 104 weeks of continuous therapy published in the Journal of the European Academy of Dermatology and Venereology
    • 30 Jan 2024 According to a Eli Lilly Canada Inc. media release, OLUMIANT (baricitinib) received regulatory approval for alopecia areata indication via Notice of Compliance (NOC) from Health Canada,The approval is based on BRAVE-AA1 and BRAVE-AA2 trials
    • 22 Nov 2023 Results of Post-, pooled Analysis from BRAVE AA1 and BRAVE AA2, published in the Dermatology and Therapy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top